GM3-Functionalized Nanoparticles for HIV-1 Interaction Studies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current models for studying HIV-1 interactions with host cells are hindered by the complexity of cellular and viral surfaces, making it difficult to decouple physical and chemical interactions, and to characterize the role of specific host-encoded viral surface functionalities, particularly the GM3-mediated interactions between HIV-1 and CD169 on dendritic cells.
Innovation Solution
Development of artificial virus nanoparticles (AVNs) with a defined ganglioside GM3-containing mixed lipid layer coated around a metal core, which mimics the HIV-1 surface to facilitate specific binding to CD169-expressing cells, allowing for the study of GM3-mediated interactions without viral envelope glycoproteins or host-derived glycolipids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional virus models are used to study HIV-1 interactions, then the model includes complete viral surface functionalities, but the compositional complexity of cellular and viral surfaces makes it difficult to decouple physical and chemical interactions
Solution Approach 1:
The patent extracts and isolates the specific GM3 glycosphingolipid component from the complex viral surface, creating simplified artificial virus nanoparticles that contain only the GM3 lipid without other viral envelope glycoproteins or host-derived glycolipids. This extraction allows researchers to study GM3-CD169 interactions in isolation, decoupling this specific chemical interaction from the complexity of the complete viral surface.
Solution Approach 2:
The patent segments the viral surface into discrete, controllable components by creating artificial nanoparticles with defined lipid compositions. The GM3-containing mixed lipid layer is segmented as a distinct functional element that can be independently controlled and studied, separate from other viral surface components.
2Device complexity
If artificial virus nanoparticles with defined lipid composition are used, then the complexity of surface interactions is reduced, but the model may lack other viral surface functionalities
Solution Approach 1:
The patent applies local quality by creating artificial virus nanoparticles with a defined ganglioside GM3-containing mixed lipid layer that specifically mimics the local GM3-rich domains on HIV-1 surfaces. This localized mimicry of specific viral surface functionalities (GM3 interactions) is achieved without requiring complete replication of all viral surface components, as the GM3-mediated CD169 binding is the specific function being studied.
3Measurement precision
If bright labels are used for optical tracking of virus trafficking, then temporal resolution is improved, but the observation time is limited
Solution Approach 1:
The patent utilizes the intrinsic optical properties of gold nanoparticles, which exhibit characteristic color changes based on their size and aggregation state. The AVNs display distinct colorimetric signals that enable optical tracking without requiring additional bright labels, thereby extending observation time while maintaining sufficient temporal resolution for studying virus trafficking dynamics.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The GM3-functionalized AVNs demonstrate a unique spatial distribution in CD169-expressing cells, mimicking HIV-1 sequestration and preserving infectivity, providing a more accurate model for studying HIV-1 trafficking and enabling targeted delivery to immune cells.
Implementation Method 1
The GSL that mediates the glycoprotein-independent interactions between HIV-1 and mature DCs was identified as monosialodihexosylganglioside (GM3), and the type 1 interferon inducible Siglec1, CD169, has been identified as the corresponding receptor that recognizes GM3 present in the membrane of HIV-1 particles.
Implementation Method 2
adding a nanoparticle of described herein to a CD169-expressing eukaryotic cell under conditions that permit the nanoparticle to be endocytosed into the CD169-expressing eukaryotic cell
Data Source
AI summary
Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nanoparticles are endocytosed by the CD169+ expressing cells.